demo · 222 papers with claims · 178 for outreach · 8 old · 36 reviews
<2016
Filtered out
New strategies in ovarian cancer treatment
Immunotherapy approaches in the treatment of malignant brain tumors
Oncolytic Viruses in Cancer Treatment
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor
Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV‐1 Virus
Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma
Development of oncolytic virotherapy: from genetic modification to combination therapy
Personalizing Oncolytic Immunovirotherapy Approaches
Combining oncolytic viruses with immune cell therapy as treatments for cancer: OV, CAR T-cell, and NK combinations
Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma
Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Exploring novel strategies of oncolytic viruses and gut microbiota to enhance CAR-T cell therapy for colorectal cancer
Armed oncolytic viruses: A kick-start for anti-tumor immunity
Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immuno
CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Block
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of He
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
Recent developments with immunotherapy for hepatocellular carcinoma
Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity.
Using oncolytic viruses to exploit endogenous TCR signaling for modulation of CAR T phenotype and function against solid
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy
EXTH-55. ANTI-TUMOR ACTIVITY OF A NEW ONCOLYTIC ADENOVIRUS DELTA-24-RGDOX-IL15 CO-EXPRESSING OX40L AND IL-15
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Harnessing the immune system to improve cancer therapy
Revolutionizing Cancer Treatment: Unleashing the Power of Combining Oncolytic Viruses with CAR-T Cells.
A viral Odyssey
Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells
Oncolytic Virotherapy: From Bench to Bedside
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects
Recent progress in combination therapy of oncolytic vaccinia virus
Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
Immunotherapy for hepatocellular carcinoma: Current and future
A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept.
Generation and characterization of HSV-1 based oncolytic viruses towards an innovative therapeutic approach for TNBC
T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
847 CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de
hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitum
Data from An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma
Abstract CT541A: Oncolytic viral reshaping of the tumor microenvironment to promote CAR T cell therapy for glioblastoma
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD4
Abstract 5072: “Armed” oncolytic herpes simplex virus enables CD19 CAR-T for solid tumor cell treatment as a combination
Abstract 2314: Pharmacology studies of chimeric antigen receptor (CAR) T cells in luminescent xenograft and 3D in vitro
Abstract A61: Human leukocyte antigen G as a novel target for switch-based chimeric antigen receptor natural killer cell
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Abstract 4814: Development of a novel claudin-6-targeting CAR-T cell
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function
Killers 2.0: NK cell therapies at the forefront of cancer control
Synergistic enhancement of γδ T cell cytotoxicity against tumor spheroids through B7H3 CAR and zoledronate sensitization
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Targeting the IDO1 pathway in cancer: from bench to bedside
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Prospects for combined use of oncolytic viruses and CAR T-cells
CAR T cells in solid tumors: challenges and opportunities
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns
Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunothera
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-
Stochastic Impulsive Dynamical Model
White paper on microbial anti-cancer therapy and prevention
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Ant
Current and future immunotherapy approaches in ovarian cancer
An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma
Cancer-associated inflammation: pathophysiology and clinical significance
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
Engineering Axl specific CAR and SynNotch receptor for cancer therapy
New Approaches on Cancer Immunotherapy
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.
Qualitative Optimization of Oncolytic Virotherapy and Immune Therapy Combination Treatments
The Current Status of Gene Therapy for the Treatment of Cancer
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
Current Immunotherapies for Glioblastoma Multiforme
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
Manipulating T-cell metabolism to enhance immunotherapy in solid tumor
Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy
New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies
Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.
Lung cancer immunotherapy: progress, pitfalls, and promises
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Glioblastoma Treatment: State-of-the-Art and Future Perspectives
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies
Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances
Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell
A Mechanistic Model of Oncolytic Virus–CAR T Therapy Identifies Memory-Dependent Control of Solid Tumors
Oncolytic viruses: overcoming translational challenges
Endogenous T cells prevent tumor immune escape following adoptive T cell therapy
Emerging therapies for glioblastoma: current state and future directions
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
asad@ut.ac.ir
CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro
Simon.Wu@legendbiotech.com
Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells s
hideho.okada@ucsf.edu
Current Advances in Immunotherapy for Glioblastoma
Bartlettdl@upmc.edu
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficac
wangg@xzhmu.edu.cn
Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo
aposey@pennmedicine.upenn.edu
Driving cars to the clinic for solid tumors
bramsonj@mcmaster.ca
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
cjune@upenn.edu
Cancer immunotherapy comes of age and looks for maturity
homi@mail.nih.gov
Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours
mcaligiuri@coh.org
An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma
lt.cai@siat.ac.cn
Bioorthogonal oncolytic-virus nanovesicles combined bio-immunotherapy with CAR-T cells for solid tumors.
wujunhua@nju.edu.cn
Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment
dongjie@nju.edu.cn
Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tum
rrockne@coh.org
CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma
olin_liang@brown.edu
Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding
laurelian@som.umaryland.edu
Oncolytic viruses as immunotherapy: progress and remaining challenges
zhaox@nanoctr.cn
Progress in oncolytic viruses modified with nanomaterials for intravenous application
h.pandha@surrey.ac.uk
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
yiweichu@fudan.edu.cn
New Chimeric Antigen Receptor Design for Solid Tumors
francesca.delbufalo@opbg.net
CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies
zhudi@fudan.edu.cn
Clinical cancer immunotherapy: Current progress and prospects
wangpengju@zzu.edu.cn
Oncolytic vaccinia virus and cancer immunotherapy
yshi@bucm.edu.cn
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
mingliu721@aliyun.com
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
steven.katz@trisaluslifesci.com
Assessing the Future of Solid Tumor Immunotherapy
jiangmin1023@suda.edu.cn
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorect
jennifer.altomonte@tum.de
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil
zhuz4@upmc.edu
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
cmccloskey@ohri.ca
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
gustavodubois@caxias.ufrj.br
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
wirth.thomas@mh-hannover.de
Prospects and Challenges for T Cell-Based Therapies of HCC
peter.malin@mh-hannover.de
Oncolytic Adenovirus in Cancer Immunotherapy
denis.migliorini@unige.ch
Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors
christian.linares@nhs.net
Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
j.h.e.kuball@umcutrecht.nl
Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas
wangman@qdu.edu.cn
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
abhat@sidra.org
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid t
rabkin@mgh.harvard.edu
Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells
Falak.r@iums.ac.ir
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
ayoon@hanyang.ac.kr
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
liujiyan1972@163.com
Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
ayang@coh.org
Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastr
j.rommelaere@dkfz-heidelberg.de
Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immun
fangm@im.ac.cn
Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy
yuanwangnk@nankai.edu.cn.
OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment
10zhuangboya@rdfzcygj.cn
An approach to increase efficacy against triple negative breast cancer using an engineered multigenic vaccinia virus com
guozs@upmc.edu
The 2018 Nobel Prize in medicine goes to cancer immunotherapy
akbarimo@tbzmed.ac.ir
Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based im
peng_wang@fudan.edu.cn
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immuno
qizhao@um.edu.mo
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of
engeland@uni-wh.de
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
sgwangtjm@163.com
Enhanced cellular therapy: revolutionizing adoptive cellular therapy
qianchu@tjh.tjmu.edu.cn
The role of neoantigen in immune checkpoint blockade therapy
xielu@sibpt.com
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
gdotti@med.unc.edu
Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy